Monthly Archives: October 2010

Hepatitis C Cont…

In addition to my previous post on Hepatitis C drug development, BMS also updated new biotech development which is a novel Interferon in Development for the Treatment of Hepatitis C (PEG-Interferon Lambda). PEG-Interferon lambda is a novel and potential first-in-class interferon in development … Continue reading

Posted in Drug developments & targets | Leave a comment

Hepatitis C Newer drugs and Combinations

Drug makers including Merck & Co., Johnson & Johnson and Bristol-Myers Squibb Co/Gilead have been racing to come up with new treatments for Hepatitis C. Telaprevir: Telaprevir is co-developed by Vertex and Johnson&Johnson.  Telaprevir shows promising results in Phase 3 studies … Continue reading

Posted in Daily interesting IP news | Tagged , , , , | Leave a comment

India: Cipla’s Oppositions compilation

This is an attempt to collect Cipla’s oppositions (pre/post) from publically available resources Application/Patent No Applicant/Patentee Drugs 329/DELNP/2004 Tibotec Intermediate IN/PCT/2002/00497/DEL OSI Pharma Erlotinib polymorph 1647/DELNP/2000 Tibotec Tenofovir/emtricitabine 3383/DELNP/2005 Gilead Tenofovir combinations 896/DEL/2002 Gilead Tenofovir 2076/DEL/1997 Gilead Tenofovir 3598/DELNP/2004 Tibotec … Continue reading

Posted in Uncategorized | Leave a comment

Fabry disease and Drug Development

Fabry disease is rare inherited enzyme deficiency disease and it is named after its discoverer  Johannes Fabry.  A deficiency of the enzyme alpha galactosidase A due to mutation causes a glycolipid known as globotriaosylceramide (abbreviated as Gb3, GL-3, or ceramide trihexoside) to … Continue reading

Posted in Uncategorized | 2 Comments

CI & Patent News 30/10/2010

1) Astellas Pharma has submitted marketing authorization application to Japan MOH for approval of Degarelix for treating prostate cancer Degarelix is Gonadtropin releasing hormone (GnRH) blocker. Degarelix was approved for the treatment of prostate cancer by the U.S. Food and Drug … Continue reading

Posted in Daily interesting IP news | Leave a comment

CI & Patent News 28/10/2010

Teva to Acquire Theramex, Merck KGaA’s European Based Women’s Health Business Theramex is speciality pharmaceutical company focused on Women health and markets various products, like gynecology, osteoporosis, peri-menopause, menopause and contraceptives, in more than 50 countries. Theramex is developing new contraceptive … Continue reading

Posted in Daily interesting IP news | Leave a comment

CI & Patent News 27/10/2010

1) Abbott Sues Anchen on Paricalcitol Capsules 1 mcg, 2 mcg, and 4 mcg. Patent in suit US 5,587,497 which expires on Jun 24, 2014 in US assigned to Wisconsin Alumni Research Foundation (Complaint) (Bloomberg) 2) Low cost HIV/AIDS drugs … Continue reading

Posted in Uncategorized | Leave a comment

Dr. Reddy’s expands portfolio in Russia & CIS through in-licensing deals

[Original link] [DRL press release] Dr Reddy’s Laboratories (DRL) today said it has entered into an agreement with drug major Cipla and UK-based Vitabiotics to market over-the-counter (OTC) and prescription drugs, besides nutraceutical products, in Russia and CIS countries. As per … Continue reading

Posted in Uncategorized | Leave a comment

CI & Patent Related News 25/10/2010

1) Brazil Supreme court of justice (STJ) once again held that pipeline patents expiry would be calculated from first priority date of foreign filing (as it was held in seledinafil and Atorvastatin) (Brazil Patent office) (IP tango) Brazil Patent No: … Continue reading

Posted in Uncategorized | Leave a comment

Daily CI & Patents News: 22/10/2010

Depomed Receives $5 Million Milestone Payment for Delivery of Formulation (Depomed press release); Depomed had developed four prototype formulations and one of them meets required specifications. This is development towards fixed dose combination of canagliflozin and metformin ER. Note: Depomed is … Continue reading

Posted in Uncategorized | Leave a comment